Previous close | 1.2900 |
Open | 1.3000 |
Bid | 1.2500 x 600 |
Ask | 1.2800 x 600 |
Day's range | 1.2300 - 1.3250 |
52-week range | 0.8000 - 2.1000 |
Volume | |
Avg. volume | 1,212,622 |
Market cap | 142.429M |
Beta (5Y monthly) | -0.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2700 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.50 |
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A
Amidst robust revenue growth and operational efficiencies, OptiNose Inc (OPTN) sets a positive trajectory for 2024.